On-Demand Webinar

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Watch this on-demand Q&A on using mechanistic modeling to assess feasibility and prioritize biotherapeutic candidates…

CertaraJuly 17, 2026

Webinar

Integrated mechanistic modeling approaches in oncology drug development

CertaraJuly 8, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Publication

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…

CertaraJune 4, 2026

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

CertaraJune 2, 2026

Publication

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

This review explores how artificial intelligence (AI), machine learning (ML), and quantitative systems pharmacology (QSP)…

CertaraJune 2, 2026

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

Publication

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

This publication highlights how pharmacometric modeling, supported by Certara, was used to inform dose selection…

CertaraMarch 25, 2026

On-Demand Webinar

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

Watch this on-demand webinar to learn how model-informed strategies using PopPK, PBPK, and QSP can…

CertaraMarch 25, 2026

Biologics

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Integrated mechanistic modeling approaches in oncology drug development

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Applying AI-Driven Biosimulation to Drug Discovery

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

ADC Dose Optimization: Applying Model-Informed Strategies in Development

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

Newsletter sign up

Quick links

Solutions

Contact